RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange that " the appointment of Shri Tejendra Khanna as Lt. Governor of Delhi, he has resigned from the Directorship of Ranbaxy Laboratories Limited effective April 08, 2007".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated April 03, 2007, titled "Terapia Ranbaxy receives GMP Certificate renewal from National Agency of Medicine for Bucharest site". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03042007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 02, 2007, titled "Ranbaxy's Drug Discovery Team achieves significant Milestone in GSK Research Collaboration; Development Candidate approved for Respiratory Inflammation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_020407.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "2nd Interim dividend of Rs. 6 (Rupees Six) per share for the year ended December 31, 2006 declared by the Board at its meeting held on March 29, 2007 will be paid on or before April 20, 2007".

Ranbaxy Laboratories Ltd has informed the Exchange that the Share Transfer Books of the Company for the purpose of Annual General Meeting will remain closed from May 25, 2007 to May 31, 2007 (both days inclusive). Annual General Meeting has been fixed for May 31, 2007.

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of the Audited Accounts for the year ended December 31, 2006, approved by the Board at its meeting held on March 29, 2007.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Res_29032007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 29, 2007, titled "Ranbaxy Annual Audited Results for the year 2006 - Net Profit up 95% at Rs 5,154 MN. Global Sales at Rs 60,652 MN, + 17% Growth; Board approves 2nd interim dividend of 120% taking total dividend for 2006 to 170%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR1_29032007.zip target=NEW> For more details clic

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 28, 2007, "Ranbaxy launches Osovair for the treatment of Asthma - World's first novel product of its kind introduced in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyPR_28032007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that April 05, 2007 has been fixed as the Record Date for determination of entitlement of 2nd Interim Dividend for the year ended December 31, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 16, 2007, titled "Ranbaxy receives tentative USFDA approval to manufacture and market Zolpidem Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_160307.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "While it is not Ranbaxy's policy to comment on M&A proposals but in view of the erroneous reports in sections of the media on the bids for the Merck Generics Business, Ranbaxy wishes to clarify that it has made a non binding bid for the asset, at a value it considers fair and reasonable. The figure of USD 6 Bn mentioned in the media reports is factually incorrect and speculative". Further, a copy of the press statement issued by the company in this regard dated March 13, 2007, shall be available on the NSE website (http://www.nseindia.c

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 11, 2007, titled "Dr. Himadri Sen to join Ranbaxy as President R&D". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12032007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that "an exclusive e-mail ID for registering investors complaints already exists in the Company that is secretarial@ranbaxy.com. The said e-mail ID had already been prominently displayed on the Company's website i.e. www.ranbaxy.com under Investor Relations>Contact".

Ranbaxy Laboratories Ltd regarding a press release dated March 07, 2007, titled "Terapia Ranbaxy gets Market Authorisations for 20 new products". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_070307.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated March 01, 2007, titled "PPD Licenses Statin from Ranbaxy Laboratories". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_010307.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 22, 2007, titled "Terapia Ranbaxy receives EU compliance for manufacturing and import authorization". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_220207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press statement, dated February 21, 2007, titled "Ranbaxy Promoters not to sell any part of their equity stakes in Ranbaxy - deny press reports." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21022007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press statement dated February 15, 2007. The details of the press statement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_statement_160207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 13, 2007, titled "Ranbaxy products listed on AOK, Germany's largest Health Insurance". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13022006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 12, 2007, titled "Ranbaxy Launches Atorvastatin In Denmark." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_press_130207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 08, 2007, titled "Ranbaxy Gains Final US FDA approval for Sertraline Hydrochloride Tablets." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_08022007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 07, 2007, titled "Ranbaxy announces global entry into Biosimilars with Zenotech - Targets EU markets first". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR__070207.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 06, 2007, titled "Ranbaxy Signs a New R&D Agreement with GSK." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06022007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 30,2007, titled "Ranbaxy gains FDA approval to market Amoxicillin and Clavulanate Potassium for Oral Suspension USP". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31012007.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 29,2007, titled "Ranbaxy launches two NDDS Urology products in India - Niftran developed in-house; Eligard in-licensed from US drug company". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pressrelease_290107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 26, 2007, titled "Canadian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_270107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "The Board of Directors at its meeting held today i.e. January 18, 2007 has approved the following : 1) Unaudited Financial Results (Provisional) for the fourth quarter and year ended December 31, 2006. 2) Appointment of Mr. Atul Sobti, Chief Operating Officer as a Whole-time Director on the Board of Company. 3) Acquisition of a strategic stake of 14.9% in Krebs Biochemicals and Industries Ltd, Hyderabad".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 18, 2007, titled "Ranbaxy records Robust Growth for Q4 2006, Net Profit up 167% at Rs 1,859 MN. Global Sales at Rs 17,077 MN, + 22% Growth - Annual Sales touch Rs 60,698 MN, + 17%, Net Profit up 97% at Rs 5,204 MN". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_180107.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that: "The ESOPs Allotment Committee of Directors at its meeting held today i.e. January 10, 2007 has allotted 91,857 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Share Capital of the Company post allotment is 372778821 Equity Shares of Rs.5 each aggregating Rs.1863894105".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 02, 2007, titled "Ranbaxy Granted Final USFDA Approval to Manufacture and Market Atenolol Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_020120076.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 21, 2006, titled "Ranbaxy Granted Final USFDA Approval To Market Simvastatin 5, 10, 20 And 40 MG Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Press2_211206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 20, 2006, titled "Australian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_press_211206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated December 18, 2006, titled "Ranbaxy and DST, Govt. of India, join hands in the area of New Drug Discovery Research." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_18122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 14, 2006, titled "Ranbaxy granted final USFDA approval to manufacture and market CEFPROZIL Anti-Infective Tablets". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_141206.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, December 11, 2006, titled "Ranbaxy Appoints Atul Sobti as COO". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 1, 2006 titled "Ranbaxy acquires Be-Tabs Pharmaceuticals, the 5th largest generics company in South Africa for USD 70 MN". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR2_01122006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 30,2006, titled "Ranbaxy organizes WALKATHON' 06 in Mumbai, India, on World Aids Day - For the first time in India, Doctors to come together to express solidarity; Ranbaxy also introduces Paediatric ARV combination medicines in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_0112006.zip target=NEW> For more de

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated November 15, 2006, titled "Ranbaxy granted favorable decision by the U.S. Court of Appeals regarding Marketing Exclusivity for SIMVASTATIN 80 mg-Decision has wide-ranging implications for Ranbaxy as well as other generic pharmaceutical manufacturers". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15112006.zip target=NEW> Fo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated November 03, 2006, titled "Ranbaxy Receives Tentative USFDA Approval to Manufacture and Market Cetirizine Hydrochloride Syrup". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03112006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press statement, dated October 30, 2006, titled "Patent Victory in Spanish Court favouring Ranbaxy on Atorvastatin unaffected." The details of the press statement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_310102006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated October 23, 2006, titled "Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for NCE Drug in the Gastroenterology Segment - Marketing rights in India, Bangladesh and Nepal". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_231006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Record Date for determination of entitlement of the interim dividend has been fixed as November 03, 2006. Interim Dividend will be paid to the eligible shareholders on or before November 14, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated October 19, 2006, titled "Ranbaxy Q3 PAT Up 651% at Rs.1,404 MN as Global Sales Scale Rs.16,404 MN, Up 26%." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19102006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange that the Board of Directors at its meeting held on October 19, 2006 has approved the payment of Interim Dividend of 50% (@ Rs. 2.50 per share of par value of Rs. 5 each) for the year ending December 31, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on October 11, 2006 has allotted 32,800 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid up Equity Share Capital of the Company post allotment is 372686964 Equity Shares of Rs.5 each aggregating Rs. 1863434820.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 06, 2006, titled "Ranbaxy Signs Licensing and Supply Agreement to Market a Second Licensed Generic in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_06102006.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 27, 2006, titled "Ranbaxy launches 'Storvas', the first generics version of Atorvastatin in Malaysia - earlier introduced the first generic alternative of Oseltamivir". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_270906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 22,2006, titled "Ranbaxy in pact with Gilead Sciences anti-HIV drug Tenofovir". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_250906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 21, 2006, titled "Ranbaxy receives approval to commercialize Furosemide Tablets in the US". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_210906.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 18, 2006, titled "Ranbaxy in-licenses NDDS cardiovascular drug from Ethypharm for Indian market", being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).